Uta Beauty (ULTA) says no change in consumer shopping behaviour has emerged entering Q3
Newsquawk Staff ·
- Average member spend increased, with consistent behaviour and higher average spend across every income cohort and age demographic.
What it means
Mid-quarter commentary on consumer behaviour from a discretionary retailer is the kind of read-through the market mines for signals on the broader consumer, since beauty has historically been treated as a resilient category whose softness, when it appears, tends to precede weakness elsewhere in discretionary spending. The notable element here is the claim of consistency across income cohorts, which pushes against the trading-down narrative that has dominated recent retail prints; in past cycles, divergence between higher and lower income spending has been the early tell of consumer stress, while uniformity has usually meant the cycle still has room. What distinguishes this from a hard print is the absence of figures: management characterizations of traffic and ticket have historically proven softer evidence than comp and margin disclosure, and the market has tended to treat them as directional at best until the formal release. Worth noting is the usual sequence: peer commentary in the same space, then the beauty category data points, then the quarter itself, with any revision to guidance carrying more weight than the qualitative colour. The read is supportive of the consumer-resilience case but is testimony rather than data.
- US FDA approves subcutaneous induction regimen for AbbVie’s (ABBV) Skyrizi for adults with moderately to severely active Crohn’s disease
- Kimi K3.1 Pro AI model builds GTA VI-style (TTWO) playable game demo in just 10 hours for USD 52, developer claims on X; showcases AI’s ability to generate video game experiences - UNCONFIRMED
- OpenAI expects future AI models to be capable of identifying and exploiting vulnerabilities that are currently unknown, according to a blog post
- Texas Attorney General Ken Paxton sues OpenAI and CEO Sam Altman for lying to users and harming Texans
- Frasers (FRAS LN) acquires an additional 0.29% stake in Hugo Boss (BOSS GY) for EUR 7.6mln; Hugo Boss now becomes a subsidiary of Frasers since stake is over 50%
Related headlines
- Daily US Earnings Estimates: 26th October 2026: VZ, WELL1 day ago
- The Trump administration plans to introduce voluntary “US Caught Seafood” labels to help consumers identify seafood origins, according to CBS1 day ago
- Bristol Myers Squibb (BMY) spokesperson says the company has identified the cause of an earlier Car-T safety signal; will look to resume the paused trials in 20271 day ago
- OpenAI reveals plans for an in-house exabyte-scale storage system1 day ago
- Republican Senator Blackburn has raised concerns about Meta’s (META) plans to update its commercial terms, warning that the changes could “exploit American creators and businesses,” according to a letter1 day ago
- CNBC speculates that Verizon (VZ) would most likely be involved in the context of a partnership with SpaceX (SPCX)1 day ago
- Ukraine President Zelensky says the Tesla (TSLA)/SpaceX (SPCX) Starlink and Starshield service remains slowed1 day ago
- US EQUITY OPEN: Breadth poor at the open: Energy leads gains on oil rally, Tech sees slight bounce1 day ago
- Meta (META) says it will extend the implementation date of updated commercial terms to November 20th (prev. October 30th); extension will allow it to explain the changes to partners and stakeholders1 day ago
- Abbott (ABT) presents new ESMO data showing 30% absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer1 day ago
- Daily US Equity Opening News: SPCX explores access to 80K US cell sites; OpenAI nears USD 30bln funding at $1.25T valuation1 day ago
- US BROKER MOVES: HESM upgraded at Raymond James; NCLH downgraded at JPM1 day ago
- Oracle (ORCL) to invest USD 1bln in partner ecosystem over 4 years1 day ago
- Bristol-Myers Squibb (BMY) says Iza-Bren reduced the risk of progression or death by 59% in Phase 3 breast cancer study; median PFS 8.2 months vs 4.0 months for chemotherapy; cORR 40.5% vs 20.2%; mDOR 6.9 vs 4.2 months1 day ago
- American Express (AXP) Q3 2026 (USD): EPS 5.42 (exp. 4.50), Revenue 20.1bln (exp. 20.1bln)1 day ago